WO2012119113A3 - Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures - Google Patents

Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures Download PDF

Info

Publication number
WO2012119113A3
WO2012119113A3 PCT/US2012/027574 US2012027574W WO2012119113A3 WO 2012119113 A3 WO2012119113 A3 WO 2012119113A3 US 2012027574 W US2012027574 W US 2012027574W WO 2012119113 A3 WO2012119113 A3 WO 2012119113A3
Authority
WO
WIPO (PCT)
Prior art keywords
lung cancer
subject
cell lines
drug sensitivity
cancer cell
Prior art date
Application number
PCT/US2012/027574
Other languages
French (fr)
Other versions
WO2012119113A2 (en
Inventor
Hua Gong
Sharat Singh
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Priority to EP15153870.9A priority Critical patent/EP2908132B8/en
Priority to EP12708484.6A priority patent/EP2681552A2/en
Priority to CA2828052A priority patent/CA2828052A1/en
Publication of WO2012119113A2 publication Critical patent/WO2012119113A2/en
Publication of WO2012119113A3 publication Critical patent/WO2012119113A3/en
Priority to US13/968,345 priority patent/US20140057798A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a method for predicting therapeutic efficacy or response to an anticancer drug or a combination of anticancer drugs in a subject having lung cancer comprising analyzing a sample obtained from the subject to determine the presence, expression level, activation level, or genotype of one or more markers to obtain a marker profile, and comparing the marker profile with known marker profiles obtained from one or more lung cancer cell lines. As such, the present invention is particularly useful in predicting therapeutic efficacy or response to one or more anticancer drugs by analyzing one or a panel of pathway biomarkers and/or mutated genes in tumor tissue obtained from a subject with lung cancer to guide treatment options for the subject based upon similarities in marker profiles obtained from the tumor tissue and lung cancer cell lines and the drug sensitivity of those lung cancer cell lines.
PCT/US2012/027574 2011-03-02 2012-03-02 Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures WO2012119113A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP15153870.9A EP2908132B8 (en) 2011-03-02 2012-03-02 Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
EP12708484.6A EP2681552A2 (en) 2011-03-02 2012-03-02 Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
CA2828052A CA2828052A1 (en) 2011-03-02 2012-03-02 Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
US13/968,345 US20140057798A1 (en) 2011-03-02 2013-08-15 Prediction of drug sensitivity of lung tumors based on molecular genetic signatures

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161448479P 2011-03-02 2011-03-02
US61/448,479 2011-03-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/968,345 Continuation US20140057798A1 (en) 2011-03-02 2013-08-15 Prediction of drug sensitivity of lung tumors based on molecular genetic signatures

Publications (2)

Publication Number Publication Date
WO2012119113A2 WO2012119113A2 (en) 2012-09-07
WO2012119113A3 true WO2012119113A3 (en) 2013-02-28

Family

ID=45816011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/027574 WO2012119113A2 (en) 2011-03-02 2012-03-02 Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures

Country Status (6)

Country Link
US (1) US20140057798A1 (en)
EP (2) EP2681552A2 (en)
CA (1) CA2828052A1 (en)
ES (1) ES2734673T3 (en)
HK (1) HK1213976A1 (en)
WO (1) WO2012119113A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012154987A1 (en) 2011-05-10 2012-11-15 Nestec Sa Methods of disease activity profiling for personalized therapy management
JP2015505959A (en) * 2011-12-05 2015-02-26 ネステク ソシエテ アノニム Methods of selecting treatment for patients with cancer
CN104838270A (en) 2012-10-05 2015-08-12 雀巢产品技术援助有限公司 Methods for predicting and monitoring mucosal healing
EP2954329A1 (en) 2013-02-05 2015-12-16 Nestec S.A. Methods of selecting combination therapy for colorectal cancer patients
EP2954068B8 (en) 2013-02-05 2018-10-31 Pierian Holdings, Inc. Drug selection for non-small cell lung cancer therapy
KR101418970B1 (en) * 2013-03-20 2014-07-11 (주)제욱 A predictive biomarker for combination therapy of EGFR and MET inhibitors in non-small cell lung cancer with wild type EGFR
AU2014269946A1 (en) 2013-05-21 2015-12-03 Nestec S.A. Methods for predicting and improving the survival of colorectal cancer patients
WO2014203152A1 (en) * 2013-06-18 2014-12-24 Novartis Ag Pharmaceutical combinations
EP3033434A2 (en) * 2013-08-14 2016-06-22 Qiagen Mansfield, Inc. Compositions and methods for multimodal analysis of cmet nucleic acids
EP3719137A1 (en) * 2013-09-05 2020-10-07 Memorial Sloan-Kettering Cancer Center Ddx43 as a biomarker of resistance to mek1/2 inhibitors
WO2015110989A1 (en) 2014-01-23 2015-07-30 Nestec S.A. Biomarker panel for assessment of mucosal healing
MX2016013027A (en) 2014-04-04 2017-05-23 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer.
WO2015164743A2 (en) 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
EP3176269B1 (en) * 2014-07-29 2020-12-02 Wellmarker Bio Co., Ltd. Inhibitors of met and igsf1 for treating cancer
MX2017004742A (en) 2014-10-20 2017-07-20 Nestec Sa Methods for prediction of anti-tnf alpha drug levels and autoantibody formation.
JP6950123B2 (en) * 2016-08-04 2021-10-13 静岡県 How to determine the risk of developing cancer
KR20200009095A (en) 2017-05-31 2020-01-29 프로메테우스 바이오사이언시즈, 인크. How to evaluate mucosal healing in patients with Crohn's disease
US11651860B2 (en) 2019-05-15 2023-05-16 International Business Machines Corporation Drug efficacy prediction for treatment of genetic disease
US11651841B2 (en) 2019-05-15 2023-05-16 International Business Machines Corporation Drug compound identification for target tissue cells
CN110232978B (en) * 2019-06-14 2022-05-17 西安电子科技大学 Cancer cell line treatment drug prediction method based on multidimensional network
WO2024064866A2 (en) * 2022-09-22 2024-03-28 Astrin Biosciences, Inc. Tumor cell profiling-based therapeutic targeting of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532138A (en) 1990-04-26 1996-07-02 Behringwerke Ag Method and kits for determining peroxidatively active catalysts
US5332662A (en) 1992-07-31 1994-07-26 Syntex (U.S.A.) Inc. Methods for determining peroxidatively active substances
DE69417242T2 (en) 1993-09-03 1999-07-08 Behringwerke Ag FLUORESCENCE OXYGEN CHANNEL IMMUNITY TESTS
WO2008059515A2 (en) 2006-08-01 2008-05-22 Divyank Turakhia A system and method of generating related words and word concepts
JP5154557B2 (en) 2006-09-21 2013-02-27 ネステク ソシエテ アノニム Antibody-based arrays for detection of diverse signaling substances in rare circulating cells
ES2526211T3 (en) 2007-07-13 2015-01-08 Nestec S.A. Selection of drugs for lung cancer therapy using antibody-based matrices
CN102016581B (en) 2008-02-25 2014-07-30 雀巢产品技术援助有限公司 Drug selection for breast cancer therapy using antibody-based arrays
WO2010132723A1 (en) 2009-05-14 2010-11-18 Prometheus Laboratories Inc. Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
JP5795311B2 (en) 2009-07-15 2015-10-14 ネステク ソシエテ アノニム Drug selection for gastric cancer therapy using antibody-based arrays
KR20120110168A (en) 2009-10-20 2012-10-09 프로메테우스 레버러터리스 인코포레이티드 Proximity-mediated assays for detecting oncogenic fusion proteins

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BALKO JUSTIN M ET AL: "Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors", BMC GENOMICS, BIOMED CENTRAL, LONDON, GB, vol. 7, no. 1, 10 November 2006 (2006-11-10), pages 289, XP021022254, ISSN: 1471-2164, DOI: 10.1186/1471-2164-7-289 *
BILD ANDREA H ET AL: "Oncogenic pathway signatures in human cancers as a guide to targeted therapies", NATURE: INTERNATIONAL WEEKLY JOURNAL OF SCIENCE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 439, no. 7074, 19 January 2006 (2006-01-19), pages 353 - 357, XP002460134, ISSN: 0028-0836, DOI: 10.1038/NATURE04296 *
GONG YIXUAN ET AL: "High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507)", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, SAN FRANCISCO, CA; US, vol. 4, no. 10, 1 October 2009 (2009-10-01), pages E7273, XP002600928, ISSN: 1932-6203, [retrieved on 20091006] *
HUA C. GONG ET AL: "Signatures of Drug Sensitivity in Nonsmall Cell Lung Cancer", INTERNATIONAL JOURNAL OF PROTEOMICS, vol. 2011, 3 June 2011 (2011-06-03), pages 1 - 13, XP055030274, ISSN: 2090-2166, DOI: 10.1155/2011/215496 *
KAZUYA MACHIDA ET AL: "Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling", PLOS ONE, vol. 5, no. 10, 1 January 2010 (2010-01-01), pages e13470, XP055030560, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0013470 *
LOBODA ANDREY ET AL: "A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors", BMC MEDICAL GENOMICS, BIOMED CENTRAL LTD, LONDON UK, vol. 3, no. 1, 30 June 2010 (2010-06-30), pages 26, XP021082963, ISSN: 1755-8794, DOI: 10.1186/1755-8794-3-26 *
MUKOHARA T ET AL: "Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations", JOURNAL OF THE NATIONAL CANCER INSTITUTE, OXFORD UNIVERSITY PRESS, GB, vol. 97, no. 16, 17 August 2005 (2005-08-17), pages 1185 - 1194, XP002447440, ISSN: 0027-8874 *
S. K. TAHIR ET AL: "Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines", MOLECULAR CANCER THERAPEUTICS, vol. 9, no. 3, 1 March 2010 (2010-03-01), pages 545 - 557, XP055030325, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-09-0651 *
YAUCH R L ET AL: "Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 11, no. 24, PART 1, 15 December 2005 (2005-12-15), pages 8686 - 8698, XP002391561, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-05-1492 *

Also Published As

Publication number Publication date
EP2681552A2 (en) 2014-01-08
CA2828052A1 (en) 2012-09-07
EP2908132A2 (en) 2015-08-19
EP2908132B8 (en) 2019-06-12
US20140057798A1 (en) 2014-02-27
WO2012119113A2 (en) 2012-09-07
ES2734673T3 (en) 2019-12-11
EP2908132B1 (en) 2019-04-24
HK1213976A1 (en) 2016-07-15
EP2908132A3 (en) 2015-09-09

Similar Documents

Publication Publication Date Title
WO2012119113A3 (en) Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
WO2011153545A3 (en) Gene expression signature as a predictor of chemotherapeutic response in breast cancer
MX351626B (en) Gene expression profile algorithm and test for determining prognosis of prostate cancer.
EP4180531A3 (en) Nasal epithelium gene expression signature and classifier for the prediction of lung cancer
WO2014144657A3 (en) Compositions and methods for cancer prognosis
EP4282405A3 (en) Detection of cancer biomarkers using nanoparticles
WO2009015233A3 (en) Gefitinib sensitivity-related gene expression and products and methods related thereto
WO2014140933A3 (en) Method for the prognosis and treatment of cancer metastasis
WO2012015765A3 (en) Method for using gene expression to determine prognosis of prostate cancer
Lv et al. Epigenetic alternations and cancer chemotherapy response
WO2014057357A3 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
WO2012074904A3 (en) Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
WO2012040602A3 (en) Targeting mtor substrates in treating proliferative diseases
WO2014124339A3 (en) Use of translational profiling to identify target molecules for therapeutic treatment
WO2009003706A3 (en) Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones
WO2012009382A3 (en) Molecular indicators of bladder cancer prognosis and prediction of treatment response
MX2019013953A (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer.
WO2012101219A3 (en) Complex mirna sets as novel biomarkers for lung diseases
WO2013124740A3 (en) BRCA DEFICIENCY PROTEIN AND mRNA SIGNATURES USEFUL IN IDENTIFICATION OF PATIENTS WITH BRCA-DEFICIENT TUMORS AND PREDICTING BENEFIT OF ANTI-CANCER THERAPY IN CANCER PATIENTS
WO2011153345A3 (en) A gene expression profile of brca-ness that correlates with responsiveness to chemotherapy and with outcome in cancer patients
WO2013130465A3 (en) Gene expression markers for prediction of efficacy of platinum-based chemotherapy drugs
WO2013188823A3 (en) Cancer prognostic assays
WO2013113942A3 (en) Novel fusion genes in lung cancer
WO2013020019A3 (en) Hypoxia-related gene signatures for cancer classification
WO2012044167A3 (en) Methods and means for typing a sample comprising cancer cells based on oncogenic signal transduction pathways

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12708484

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2828052

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012708484

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE